Issue Date: June 15, 2015
Seattle And Unum Make Cancer Pact
Seattle Genetics will pay Unum Therapeutics $25 million to develop antibody-coupled T-cell receptor (ACTR) therapies for cancer. Unum combines engineered T cells with antibodies that can help them home in on cancer cells. Under the pact, which also calls for Seattle Genetics to make a $5 million equity investment in Unum, the partners will develop two ACTRs that use antibodies from Seattle Genetics.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society